• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

Therapeutic-dose anticoagulation reduces mortality risk compared with prophylactic-dose anticoagulation in patients hospitalized for COVID-19

byAdrian Wong, BHScandThomas Su
December 23, 2024
in Infectious Disease
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this meta-analysis of randomized trials involving patients hospitalized with COVID-19, therapeutic-dose anticoagulation was found to be associated with a lower 28-day mortality risk compared with prophylactic-dose anticoagulation.

2. In studies that utilized intermediate dosing, mortality risk appeared higher for therapeutic-dose versus intermediate-dose anticoagulation, and similar between prophylactic-dose and intermediate-dose anticoagulation.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Various anticoagulants have been assessed for effectiveness against thrombosis in patients hospitalized for COVID-19, but optimal drug selection and dosing remain unclear, particularly among patients with differing disease severity. This study aimed to synthesize the data from existing randomized trials to elucidate associations between anticoagulant dose and clinical outcomes. Data were collected from twenty-two studies across twenty-one countries. Overall, patients receiving therapeutic-dose anticoagulation were found to have a lower absolute 28-day mortality risk compared to those receiving prophylactic-dose anticoagulation. Therapeutic-dose anticoagulation was also associated with a higher absolute mortality risk versus intermediate-dose anticoagulation, and intermediate-dose anticoagulation was associated with little change in absolute mortality risk when compared with prophylactic-dose anticoagulation. Higher doses of anticoagulation were linked to fewer thromboembolic events but more major bleeding events. Degree of respiratory support did not seem to affect the associations between anticoagulation and these clinical outcomes. The generalizability of this study was limited by its lack of data on direct oral anticoagulants, its use of major bleeding as the only primary adverse event, and relatively few comparisons of intermediate dosing. Nevertheless, this study provided an understanding of the relationships between anticoagulant dose and short-term mortality in patients hospitalized with COVID-19.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports

RELATED REPORTS

AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality

Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings

FDA approvedFor COVID-19: Xocova (ensitrelvir), May 29, 2026→

In-Depth [systematic review and meta-analysis]: This meta-analysis aimed to characterize the associations between anticoagulant dose and various clinical outcomes among patients with COVID-19. Trials were eligible for inclusion if they randomly assigned higher-dose and lower-dose anticoagulants among hospitalized patients; anticoagulant regimens were sorted into therapeutic-dose, prophylactic-dose, and intermediate-dose. The primary outcome was all-cause mortality within 28 days following randomization; secondary outcomes included progression to invasive mechanical ventilation (IMV) or death, arterial or venous thromboembolic events, and major bleeding. Only one trial evaluated direct oral anticoagulants. Mortality data for 6297 patients receiving therapeutic- versus prophylactic-dose anticoagulation were obtained from 11 trials, yielding a summary odds ratio (OR) of 0.77 (95% CI, 0.64 to 0.93) and an absolute mortality risk of 8% for therapeutic-dose anticoagulation compared with an assumed risk of 10% for prophylactic-dose anticoagulation. There were a total of 222 thromboembolic events (summary OR, 0.48 [95% CI, 0.36 to 0.64]) and 81 major bleeding events (summary OR, 1.90 [95% CI, 1.19 to 3.05]) in this population. Mortality data for 1798 patients receiving therapeutic- versus intermediate-dose anticoagulation were obtained from 6 trials, yielding a summary OR of 1.21 (95% CI, 0.93 to 1.58) and an absolute mortality risk of 27% for therapeutic-dose anticoagulation compared with an assumed risk of 24% for intermediate-dose anticoagulation. There were a total of 121 thromboembolic events (summary OR, 0.63 [95% CI, 0.43 to 0.93]) and 46 major bleeding events (summary OR, 1.21 [95% CI, 0.66 to 2.20]) in this population. Mortality data for 3897 patients receiving intermediate- versus prophylactic-dose anticoagulation were obtained from 10 trials, which yielded a summary OR of 0.95 (95% CI, 0.76 to 1.19). There were 121 thromboembolic events (summary OR, 0.67 [95% CI, 0.45 to 1.00]) and 44 major bleeding events (summary OR, 1.22 [95% CI, 0.66 to 2.25]) in this population. Overall, this study showed potential associations between the dose of anticoagulants and mortality, thromboembolic events, and major bleeding events in patients hospitalized for COVID-19.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID thromboembolismCOVID-19direct oral anticoagulant (DOAC)heparinmortalityprophylactic anticoagulationtherapeutic anticoagulation
Previous Post

Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent HCC

Next Post

Heated mittens not found to improve physical hand function in patients with osteoarthritis

RelatedReports

Physical activity collage: an engraved bicycle, a water bottle lying on its side and a path of flat stepping stones
Artificial Intelligence

AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality

November 19, 2026
End-stage renal disease collage: a pair of kidneys, an older man, a blank dialysis machine and a loop of tubing
All Specialties

Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings

November 17, 2026
Collage on head injury in adults: a calm man beside an engraved brain drawing, a bicycle helmet and a small penlight
Chronic Disease

Spousal traumatic brain injury is associated with increased mortality in the uninjured partner

November 13, 2026
A profile of a human head with a visible brain, surrounded by descending bar graphs and doors leading into a fading background, suggesting themes of dementia and cognitive decline.
Weekly Rewinds

2 Minute Medicine Rewind November 9, 2026

November 11, 2026
Next Post

Heated mittens not found to improve physical hand function in patients with osteoarthritis

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

Adalimumab may be associated with improved outcomes in the management of pediatric Crohn's disease

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.